Different Presentations and Different Treatment Options in Blastic Plasmacytoid Dendritic Cell Neoplasms: A Case Series
International Journal of Hematology-Oncology and Stem Cell Research, cilt.19, sa.1, ss.81-85, 2025 (Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 19 Sayı: 1
- Basım Tarihi: 2025
- Doi Numarası: 10.18502/ijhoscr.v19i1.17829
- Dergi Adı: International Journal of Hematology-Oncology and Stem Cell Research
- Derginin Tarandığı İndeksler: Scopus, EMBASE
- Sayfa Sayıları: ss.81-85
- Anahtar Kelimeler: Bendamustine, Blastic plasmacytoid dendritic cell neoplasm, Chemotherapy, Minimal residual disease, Stem cell transplantation
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Blastic plasmacytoid dendritic cell neoplasms (BPDCN) are rare, aggressive hematologic neoplasms. Awareness about this neoplasm has increased after it was defined as a clonal plasmacytoid dendritic cell disease under histiocytic/dendritic cell neoplasms in the World Health Organization 2022 classification of myeloid and Histiocytic/Dendritic Neoplasms1. Therapies include chemotherapy or immunotherapy2-4 though stem cell transplantation (SCT) is the best consolidative approach in eligible patients5. Here, we present one intensive therapy-ineligible and two intensive-therapy-eligible patients with different presentations of BPDCN.